These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 27252246)

  • 1. GLP-1 Agonists in Type 1 Diabetes Mellitus.
    Janzen KM; Steuber TD; Nisly SA
    Ann Pharmacother; 2016 Aug; 50(8):656-65. PubMed ID: 27252246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
    Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
    Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.
    Xue X; Ren Z; Zhang A; Yang Q; Zhang W; Liu F
    Int J Clin Pract; 2016 Aug; 70(8):649-56. PubMed ID: 27456750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes.
    Unni S; Wittbrodt E; Ma J; Schauerhamer M; Hurd J; Ruiz-Negrón N; McAdam-Marx C
    Diabetes Obes Metab; 2018 Feb; 20(2):468-473. PubMed ID: 28862808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.
    Singh S; Wright EE; Kwan AY; Thompson JC; Syed IA; Korol EE; Waser NA; Yu MB; Juneja R
    Diabetes Obes Metab; 2017 Feb; 19(2):228-238. PubMed ID: 27717130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.
    Drab SR
    Curr Diabetes Rev; 2016; 12(4):403-413. PubMed ID: 26694823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
    Thompson AM; Trujillo JM
    Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging new therapies for the treatment of type 2 diabetes mellitus: glucagon-like peptide-1 receptor agonists.
    Lindamood CA; Taylor JR
    Clin Ther; 2015 Mar; 37(3):483-93. PubMed ID: 25659912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Plethora of GLP-1 Agonists: Decisions About What to Use and When.
    Samson SL; Garber AJ
    Curr Diab Rep; 2016 Dec; 16(12):120. PubMed ID: 27766579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Karagiannis T; Liakos A; Bekiari E; Athanasiadou E; Paschos P; Vasilakou D; Mainou M; Rika M; Boura P; Matthews DR; Tsapas A
    Diabetes Obes Metab; 2015 Nov; 17(11):1065-74. PubMed ID: 26395850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment.
    Jabbour S; Paik JS; Aleppo G; Sharma P; Gomez Valderas E; Benneyworth BD
    Endocr Pract; 2024 Aug; 30(8):701-709. PubMed ID: 38723893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus.
    Harris KB; Boland CL
    Pharmacotherapy; 2016 Sep; 36(9):1011-20. PubMed ID: 27485823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
    Chun JH; Butts A
    JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
    Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
    Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two new GLP-1 receptor agonists for diabetes.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):109-11. PubMed ID: 25372847
    [No Abstract]   [Full Text] [Related]  

  • 20. Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.
    Monami M; Dicembrini I; Nreu B; Andreozzi F; Sesti G; Mannucci E
    Acta Diabetol; 2017 Dec; 54(12):1101-1114. PubMed ID: 28932989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.